National Eye Institute (NEI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Eye Institute (NEI) sits in the top decile of US sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count).
National Eye Institute (NEI): 221 sponsored US clinical trials, 18 recruiting.
National Eye Institute (NEI) sponsors 221 registered US clinical trials on ClinicalTrials.gov, 18 of them currently recruiting, and 179 completed. 11 of these trials are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Age-related Macular Degeneration, with 8 trials.
Top-decile sponsor footprint
National Eye Institute (NEI) ranks in the top decile of sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
179 of 196 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
221 total, page 1 of 5
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
NCT06491615
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
NCT04289571
Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4
NCT04591483
Oral Metformin for Treatment of ABCA4 Retinopathy
NCT04545736
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT04339764
Perception, Sensation, Cognition and Action in Humans
NCT03407066
Clinical and Molecular Studies in Families With Inherited Eye Disease
NCT02771236
Natural History, Pathogenesis, and Outcome of Ocular Disorders
NCT02821767
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
NCT02741440
Rod and Cone Mediated Function in Retinal Disease
NCT02617966
Genetics of Inherited Eye Disease
NCT02471287
Adaptive Optics Retinal Imaging
NCT02317328
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions
NCT02077894
Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC)
NCT01778543
National Eye Institute Biorepository for Retinal Diseases
NCT01496625
Cell Collection to Study Eye Diseases
NCT01432847
Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
NCT01145196
Screening for Research Participants
NCT00655096
Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss
NCT06670989
Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma
NCT04458935
Dark Adaptation in Participants With Age-Related Macular Degeneration
NCT03225131
Natural History of Eye Diseases Related to ABCA4 Mutations
NCT01736293
Study of Dark Adaptation in Age-Related Macular Degeneration
NCT01352975
Age-Related Eye Disease Study (AREDS) Follow-Up
NCT00594672
Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis
NCT00055029
Potential Environmental Causes of Uveal Coloboma
NCT04833361
Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors
NCT04665752
Biomarkers in Ocular Inflammation and Uveitis
NCT04690829
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
NCT03845218
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
NCT03372746
Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
NCT03367767
Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
NCT03478878
Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation
NCT03478865
AMD Ryan Initiative Study (ARIS)
NCT03092492
Mothers Experiences With X-linked Retinoschisis Compared to Fathers Experiences
NCT03354403
Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
NCT02911116
Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT02941263
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
NCT02859441
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT02564978
Uveitis/Intraocular Inflammatory Disease Biobank (iBank)
NCT02656381
The Focal Electro-Oculogram in Macular Disease
NCT02225119
Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)
NCT02338973
People s Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial
NCT02317354
Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198
NCT02226835
Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa
NCT02140164
A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients
NCT01972438
Intestinal Bacteria and Ocular Inflammatory Disease
NCT01859299
Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study
NCT01915238
Color Vision as a Measure for Inherited Retinal Diseases
NCT01878032
Nitisinone for Type 1B Oculocutaneous Albinism
NCT01838655
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 62 |
| Phase 2 | 24 |
| Phase 3 | 11 |
Therapeutic Areas
What is open in the National Eye Institute (NEI) pipeline
18 recruiting of 221 indexed (8% open); 179 completed (81%).
Phase mix: 11 late (III/IV) vs 86 early (I/II) (early-phase heavy).
Top condition: Age-related Macular Degeneration (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Eye Institute (NEI): open-pipeline peers nationwide
Peers matched on 221 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Eye Institute (NEI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 221 trials (± recruiting share)
- Otsuka Pharmaceutical Development & Commercialization · 221 trials · 4% recruiting
- Florida State University · 219 trials · 21% recruiting
- Penn State University · 219 trials · 17% recruiting
- University of Louisville · 217 trials · 21% recruiting
Sponsors near 8% open enrollment (± trial volume)
- GE Healthcare · 8% recruiting · 99 trials
- HealthPartners Institute · 8% recruiting · 146 trials
- Oregon Research Institute · 8% recruiting · 62 trials
- Arcutis Biotherapeutics · 8% recruiting · 25 trials
Related
What to do with this National Eye Institute (NEI) page
221 registered trials is a research-attention snapshot, not an endorsement of National Eye Institute (NEI) or any single study.
- 18 of National Eye Institute (NEI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Age-related Macular Degeneration is the condition National Eye Institute (NEI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Age-related Macular Degeneration trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Eye Institute (NEI) pipeline card: 221 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.